Sunday, September 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

Defiance Melancarkan SPCQ: Dana Dagangan Bursa (ETF) Sasaran Harian 2X Singkat untuk SpaceX

View original at globenewswire.com
Defiance Melancarkan SPCQ: Dana Dagangan Bursa (ETF) Sasaran Harian 2X Singkat untuk SpaceX MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs hari ini mengumumkan pelancaran Defiance Daily Target 2X Short SpaceX ETF (SPCQ), sekali gus memperluas rangkaian ETF leveraj saham tunggal yang direka khas untuk pedagang a…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SPCQ is a newly established investment management company with limited operating history, and therefore there is limited performance history for investors to use as a basis for evaluation.

    60% confidence
  • SPCQ seeks daily investment results, before fees and expenses, of -2 times (-200%) the daily percentage change in the price of SpaceX (NASDAQ: SPCX) stock. The fund does not seek to achieve its stated investment objective over any period other than a single trading day.

    60% confidence
  • For periods longer than one trading day, the fund's performance will be the result of compounded daily returns, which will likely differ materially from -200% of SpaceX's return over the same period. Investors may lose their entire investment in a single trading day.

    60% confidence
  • SPCQ enters into swap agreements and options contracts based on the price of SpaceX stock (NASDAQ: SPCX) as part of its inverse investment strategy, exposing the fund to counterparty risk.

    60% confidence
  • SpaceX is a key participant in the commercial space industry, contributing to the expansion of global satellite communications and orbital launch capabilities.

    60% confidence
  • For recently listed companies, derivative instruments such as swaps and options may be limited, illiquid, expensive or unavailable, particularly shortly after an IPO or during periods of significant market uncertainty.

    60% confidence
  • Daily rebalancing of SPCQ is expected to result in a high portfolio turnover rate, which may increase transaction costs and potentially result in higher taxable distributions to shareholders.

    60% confidence
  • SpaceX's value may be significantly affected by Elon Musk's actions, decisions, and public statements. Public perception of his leadership or involvement in other ventures could influence investor sentiment and the performance of the underlying security.

    60% confidence
  • SpaceX was founded in 2002 by Elon Musk and develops and operates launch vehicles for commercial, government and defense customers, as well as providing satellite-based broadband services via the Starlink network.

    60% confidence
  • SpaceX may fail to meet publicly announced expectations regarding its business, launch operations, satellite deployment or commercial growth initiatives, which could cause the value of the underlying security to decline.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com